(Cefepime + zidebactam) is under clinical development by Wockhardt and currently in Phase III for Pyelonephritis. According to GlobalData, Phase III drugs for Pyelonephritis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cefepime + zidebactam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cefepime + zidebactam) overview
A fixed dose combination of cefepime and zidebactam (WCK-5222) is under development for the treatment of complicated urinary tract infections, complicated urinary tract infection or acute pyelonephritis. It is administered by intravenous infusion as a solution. It targets beta lactamase and penicillin binding protein 2. It was under development for ventilator associated bacterial pneumonia and hospital acquired bacterial pneumonia (HABP)/VABP.
Wockhardt is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. Its product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology, and diabetes. The company also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). It operates in India, the US, the UK, Ireland, Dubai, U.A.E. and has market presence in Brazil, France, Russia, Vietnam, Mexico, Philippines, Kenya, Nigeria, Ghana and others. Wockhardt is headquartered in Mumbai, Maharashtra, India.
For a complete picture of (Cefepime + zidebactam)’s drug-specific PTSR and LoA scores, buy the report here.